Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBITDA (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EBITDA for 9 consecutive years, with -$129.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 9.05% to -$129.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$513.9 million, a 21.95% decrease, with the full-year FY2025 number at -$513.9 million, down 21.95% from a year prior.
  • EBITDA was -$129.0 million for Q4 2025 at Denali Therapeutics, down from -$126.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $184.5 million in Q2 2023 to a low of -$133.0 million in Q1 2025.
  • A 5-year average of -$84.8 million and a median of -$99.7 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 398.4% in 2023, then tumbled 154.42% in 2024.
  • Denali Therapeutics' EBITDA stood at -$77.2 million in 2021, then fell by 21.33% to -$93.7 million in 2022, then dropped by 26.11% to -$118.2 million in 2023, then dropped by 0.07% to -$118.3 million in 2024, then fell by 9.05% to -$129.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's EBITDA are -$129.0 million (Q4 2025), -$126.7 million (Q3 2025), and -$125.2 million (Q2 2025).